The DEA acted on August 25, putting three synthetic, concentrated compounds derived from kratom's 7-OH chemical — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — into Schedule I, the same category as heroin and LSD. The order explicitly leaves natural kratom leaf alone below a set threshold. Massachusetts went further. Gov. Maura Healey and Public Health Commissioner Robbie Goldstein ordered Massachusetts's own emergency ban on August 13. It covers every form of kratom and took effect Friday, August 28. Four retailers and the American Kratom Association have each sued. The retailers want to block the state ban outright; the AKA wants to keep the federal ban from reaching past synthetic extracts into the plant itself.

Regulators Say They Don't Have Time to Split Hairs

Deaths and poison-center calls are climbing fast enough that officials say a broad ban beats a precise one.

People are dying, and gas stations are still selling this to kids. Healey put it directly: "Parents shouldn't have to be afraid that their kids are going to walk into some gas station or a convenience store and buy something that looks harmless that later they ingest or use with other substances that leaves them in really bad shape, including death." Massachusetts counts more than 100 kratom-associated deaths since 2020 and roughly 130 kratom-related poison-center calls since January 2021. 2026 alone is already nearly matching all of 2025 combined. Nationally, the CDC's poison-center data shows kratom-related reports rose 1,200% over the past decade, from 258 in 2015 to 3,434 in 2025. Attorney General Todd Blanche framed the federal action the same way: "The Justice Department is acting before these dangerous compounds become a broader threat... These are potent opioids being manufactured and sold in consumer products, often under labels that obscure their true risks." A DPH spokesperson defended going further than Washington did: the products "are not FDA-approved for medical use, are sold without consistent safety standards, and can vary widely in their ingredients and potency."

The Retailers Suing Say This Isn't About Whether Kratom Is Risky

Four shop owners say Massachusetts skipped the legal process required before banning their entire inventory.

Four shop owners say the state skipped a required step. Jay's Smoke Shop in Salem, Bhakti LLC, V & K Smoke Shop, and Ambreen & S Inc. sued Commissioner Goldstein before the ban took effect, arguing he lacked the statutory authority to declare a blanket Schedule I emergency without notice or a hearing. The retailers are careful about what they're not arguing: "Plaintiffs do not dispute that some kratom products raise genuine public-health concerns... Plaintiffs' claims concern whether the Commissioner complied with the statutes." But look at the data itself: the state's own death and poison-call numbers don't separate natural leaf from synthetic 7-OH extract. Nothing in the record justifies treating them the same. The ban took effect Friday anyway while their case remains pending.

The Kratom Industry's Own Trade Group Sided With the Feds, Not With Massachusetts

The American Kratom Association backs banning synthetic extracts but is suing to keep natural leaf legal.

The kratom industry's own lobby sued the DEA too. The American Kratom Association filed suit on August 27 against the DEA, Administrator Terrance Cole, and the Justice Department. AKA agrees with banning the synthetic compounds. It just wants a judge to confirm the order doesn't reach the natural leaf too. Lobbyist Mac Haddow: "This lawsuit is about regulatory clarity, preserving science-based oversight, and ensuring the DEA's temporary scheduling order stays focused on deliberately manufactured, concentrated opioid compounds — not natural kratom leaf." He'd already praised the DEA's original move in similar terms: enforce against "bad actors who manufacture and market dangerous concentrated opioid compounds, while preserving access to traditional botanical kratom products that comply with state Kratom Consumer Protection Acts." University of Florida pharmacy researcher Dr. Oliver Grundmann backs the distinction scientifically: "The adverse effects are self-limiting because you cannot ingest that high of an amount that you would reach concentrations of mitragynine... that are close to what we see with these extracts and semi-synthetic products."

Patients and a Recovery Doctor Both Worry the Cutoff Was Too Sudden

People managing pain, anxiety, and addiction with kratom leaf say an overnight ban leaves them with nowhere to go.

Some patients say the ban took their medicine away. Lora Romney, president of the International Plant and Herbal Alliance, managed 13 years of chronic facial nerve pain with leaf kratom after pharmaceuticals, Botox, and neurosurgery all failed her. "You're not taking all of your people into consideration," she said. Ashley Davidson, a Hull, Massachusetts resident five years sober from alcohol, says kratom kept her agoraphobia and treatment-resistant depression manageable enough to see a doctor and visit her elderly father in his nursing home. Dr. Myles Jen Kin, medical director at Recovery Centers of America in Massachusetts, doesn't call kratom safe. But he's watched kratom-related detox admissions climb from a handful a year to roughly a dozen or fifteen a week. Jen Kin worries the ban could backfire: cutting people off all at once could push some toward fentanyl or heroin instead. "If we have a massive increase, which is likely, facilities might be full," he said.

Where This Lands

The DEA banned three synthetic compounds and explicitly left natural kratom leaf alone. Massachusetts banned everything, betting that its own death and poison-call data justifies not waiting for a cleaner line between leaf and extract. The four retailers who sued DPH aren't disputing that 7-OH is risky. They're arguing the state skipped the process required by law to ban everything else. They lost anyway — the ban took effect Friday while their case is still pending. The American Kratom Association is suing the DEA from the opposite direction, trying to keep even the narrower federal rule from bleeding into the botanical leaf its members sell legally under state consumer-protection laws. And the people caught in between have the least say in how fast any of this moves: a chronic pain patient, a woman managing agoraphobia, a doctor watching his detox beds fill up.

Sources